Drägerwerk stock gains 0.28% to EUR 106.90 pre-market
Published on 11/05/2026 at 08:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points for investors
- Drägerwerk operates in medical and safety technology.
- Nine-month sales increased in the latest update, while third-quarter EBIT declined.
- Management left its 2026 targets unchanged, keeping margin execution in focus.
Drägerwerk stock traded at EUR 106.90 on Lang & Schwarz at 08:39 CET on Thursday, November 5, 2026, 0.28 percent above the Xetra close of Wednesday, November 4, 2026, at EUR 106.60.
Investors can follow the real-time quote of Drägerwerk stock as trading develops.
Sales growth meets margin pressure
Drägerwerk's latest nine-month update combined higher sales with a decline in third-quarter EBIT. The company kept its 2026 targets unchanged, leaving execution against the full-year outlook as the central investor focus.
The mixed operating picture puts attention on whether stronger demand can translate into more consistent quarterly profitability. Medical and safety technology remain the company's core business areas.
The DAX market overview provides the broader setting for German equities.
More news and analyses on Drägerwerk stock remain available for investors tracking the outlook.
